The CDER Office of Prescription Drug Promotion says Xeris Web pages for Recorlev create a misleading impression about the drugs efficacy and safety.
CDER associate director for rare diseases Kerry Jo Lee highlights the one-year successes of the Accelerating Rare disease Cure program and looks to th...
An FDA update says GE HealthCare has conducted preliminary testing on its newly manufactured neonatal incubators that suggests the potential for highe...
FDA grants Futura Medical a de novo marketing authorization for over-the-counter MED3000, a topical gel formulation for treating erectile dysfunction.
Federal Register notice: FDA issues an order to debar Luis Anarbol Moran for five years from importing any drug into the U.S.
Federal Register notice: FDA seeks comments on an information collection extension entitled Orphan Drugs 21 CFR Part 316.
BIO suggests revisions to an FDA strategic plan for modernizing the agencys data and technology systems.
Viatris asks FDA to require additional PK and PD studies to support an ARS Pharmaceuticals NDA for its ARS-1 epinephrine nasal spray.
